Lonza Group AG (LON: 0QNO)
London
· Delayed Price · Currency is GBP · Price in CHF
580.45
+13.35 (2.35%)
At close: Jan 22, 2025
Lonza Group AG Revenue
Lonza Group AG had revenue of 3.06B CHF in the half year ending June 30, 2024, with 2.52% growth. This brings the company's revenue in the last twelve months to 6.70B, up 5.97% year-over-year. In the year 2023, Lonza Group AG had annual revenue of 6.72B with 7.94% growth.
Revenue (ttm)
6.70B CHF
Revenue Growth
+5.97%
P/S Ratio
n/a
Revenue / Employee
372.00K CHF
Employees
18,000
Market Cap
37.51B GBP
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6.72B | 494.00M | 7.94% |
Dec 31, 2022 | 6.22B | 814.00M | 15.05% |
Dec 31, 2021 | 5.41B | 901.00M | 19.99% |
Dec 31, 2020 | 4.51B | 301.00M | 7.15% |
Dec 31, 2019 | 4.21B | -1.34B | -24.09% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Lonza Group AG News
- 6 months ago - Lonza Group AG (LZAGY) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 9 months ago - Lonza Group AG (LZAGY) Q1 2024 Earnings Call Transcript - Seeking Alpha
- 10 months ago - Lonza: Acceleration In Mid-Term Sales Growth - Seeking Alpha
- 1 year ago - Lonza: Excellent Growth Projections Will Sharply Increase Free Cash Flow - Seeking Alpha
- 1 year ago - Lonza Group AG (LZAGY) Q4 2023 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Lonza chairman to step down, drugmaker confirms targets, shares soar - Reuters
- 1 year ago - Lonza: The Day Has Come, And We Lower Our Expectation - Seeking Alpha
- 1 year ago - Lonza Group: Downside Scenario Already Priced In - Seeking Alpha